

# Li-Wei Dong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8194086/publications.pdf>

Version: 2024-02-01

15  
papers

1,213  
citations

840585

11  
h-index

887953

17  
g-index

17  
all docs

17  
docs citations

17  
times ranked

3440  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. <i>Cell Discovery</i> , 2020, 6, 31.	3.1	644
2	Shp2 promotes liver cancer stem cell expansion by augmenting $\beta$ -catenin signaling and predicts chemotherapeutic response of patients. <i>Hepatology</i> , 2017, 65, 1566-1580.	3.6	127
3	Acetyl-coenzyme A carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients. <i>Hepatology</i> , 2016, 63, 1272-1286.	3.6	101
4	Gankyrin has an antioxidative role through the feedback regulation of Nrf2 in hepatocellular carcinoma. <i>Journal of Experimental Medicine</i> , 2016, 213, 859-875.	4.2	48
5	The oncoprotein p28GANK establishes a positive feedback loop in $\beta$ -catenin signaling. <i>Cell Research</i> , 2011, 21, 1248-1261.	5.7	45
6	Signal regulatory protein 1 negatively regulates both TLR3 and cytoplasmic pathways in type I interferon induction. <i>Molecular Immunology</i> , 2008, 45, 3025-3035.	1.0	41
7	SVCT-2 determines the sensitivity to ascorbate-induced cell death in cholangiocarcinoma cell lines and patient derived xenografts. <i>Cancer Letters</i> , 2017, 398, 1-11.	3.2	33
8	Combination of Kras activation and PTEN deletion contributes to murine hepatopancreatic ductal malignancy. <i>Cancer Letters</i> , 2018, 421, 161-169.	3.2	26
9	PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	23
10	RPB5-Mediating Protein Promotes Cholangiocarcinoma Tumorigenesis and Drug Resistance by Competing With NRF2 for KEAP1 Binding. <i>Hepatology</i> , 2020, 71, 2005-2022.	3.6	18
11	RMP predicts survival and adjuvant TACE response in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 3432-3442.	0.8	10
12	RPRD1A stabilizes NRF2 and aggravates HCC progression through competing with p62 for TRIM21 binding. <i>Cell Death and Disease</i> , 2022, 13, 6.	2.7	10
13	PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer. <i>Cancer Letters</i> , 2021, 501, 187-199.	3.2	9
14	Metabolic Reprogramming and Its Relationship to Survival in Hepatocellular Carcinoma. <i>Cells</i> , 2022, 11, 1066.	1.8	8
15	Metabolic Reprogramming and Risk Stratification of Hepatocellular Carcinoma Studied by Using Gas Chromatography-Mass Spectrometry-Based Metabolomics. <i>Cancers</i> , 2022, 14, 231.	1.7	5